key: cord-0913465-wad5n2tr
authors: Li, Fuhai; Boon, Adrianus C.M.; Michelson, Andrew P.; Foraker, Randi E.; Zhan, Ming; Payne, Philip R.O.
title: Estrogen Hormone Is an Essential Sex Factor Inhibiting Inflammation and Immune Response in COVID-19
date: 2021-09-30
journal: Res Sq
DOI: 10.21203/rs.3.rs-936900/v1
sha: 54e909f6ee7a50af3348dd91f6e279600393b1e3
doc_id: 913465
cord_uid: wad5n2tr

Although vaccines have been evaluated and approved for SARS-CoV-2 infection prevention, there remains a lack of effective treatments to reduce the mortality of COVID-19 patients already infected with SARS-CoV-2. The global data of COVID-19 showed that men have a higher mortality rate than women. We further observed that the proportion of mortality of female increases starting from around the age of 55 significantly. Thus, sex is an essential factor associated with COVID-19 mortality, and sex related genetic factors could be interesting mechanisms and targets for COVID-19 treatment. However, the associated sex factors and signaling pathways remain unclear. Here, we propose to uncover the potential sex associated factors using systematic and integrative network analysis. The unique results indicated that estrogen hormones (ER), e.g., estrone and estriol, 1) interacting with ESR1/2 receptors, 2) can inhibit SARS-CoV-2 caused inflammation and immune response signaling in host cells; and 3) estrogen hormone is associated with the distinct fatality rates between male and female COVID-19 patients. Specifically, a high level of estradiol protecting young female COVID-19 patients, and estrogen loss to an extremely low level in females after about 55 years of age causing the increased fatality rate of women. In conclusion, estrogen hormone, interacting with ESR1/2 receptors, is an essential sex factor that protects COVID-19 patients by inhibiting inflammation and immune response caused by SARS-CoV-2 infection. Medications perturb the down-stream of ESR1/ESR2 to inhibit the inflammation and immune response can be effective or synergistic combined with other existing drugs for COVID-19 treatment.

Globally, by September 25, 2021, over 230 million 1 people were diagnosed with Coronavirus Disease 2019 (COVID- 19) , which is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). COVID-19 has a relatively high mortality rate 2 , and more than 4.7 million patients have died from the pandemic to-date 1 Though these results are promising, the effect of Remdesivir alone remains limited. In light of these challenges in terms of the prevention and treatment of COVID-19, many drugs and drug combinations are being tested on their own and in combination with Remdesivir in more than a thousand clinical trials globally. Among these drugs is dexamethasone, an FDA-approved drug, which was reported to be able to reduce the death rate of patients with severe COVID-19 3 .

However, the death rate for such patients remains high despite such potential reductions. Sex had been indicated as an essential factor in the mortality of COVID-19. The global data of showed that men have a higher mortality rate than women 4, 5 . For example, the metaanalysis was conducted, and the analysis results showed that there were 3 times more male patients requiring intensive treatment unit admission than females, whereas there is a similar proportion of men and women with COVID-19 confirmation 5 . In addition, we further observed that the proportion of mortality of female increases starting from around the age of 55 significantly (see the results). Thus, the sex difference indicated that sex related genetic factors could be an interesting mechanism and targets for COVID-19 treatment, combined with existing treatment options. Numerous studies have been reported in the literature concerning efforts to understand the signaling mechanism and identify effective targets for COVID-19 from different perspectives 6, 7, 8, 9, 10, 11, 12, 13 , like transcriptomic data analysis, proteomics data analysis, investigation of relevant protein structures, and the use of experimental and computational methodologies. However, few studies have been specifically designed for investigating sex related signaling pathways and targets. The underlying targets and signaling pathways associated with the sex difference remain unclear.

In response to the preceding gaps in knowledge, in this study, the objective is to uncover the potential sex associated factors using systematic and integrative network analysis. Specifically, we explore how protein-protein interaction screening data, transcriptomics data, signaling pathway data, protein-protein interaction signaling networks, and transcription factor-target regulatory networks can be integrated to enable such network analyses. We then go on to determine drug-target interactions and associations based upon an interrogate of the drugBank 14 and connectivity map (CMAP) databases 15, 16 in order to identify the potentially-effective targets from the drug-target interaction perspective. Our unique results with novel discoveries, i.e., estrogen hormones (ER), like estrone and estriol, 1) interacting with ESR1/2 receptors, 2) can inhibit SARS-CoV-2 caused inflammation and immune response signaling in host cells; and 3) the loss of estrogen hormones to an extremely low level after 55 years of age is associated with the mortality increasing in female. These three novel observations support estrogen hormone is an essential sex factor causing the distinct fatality patterns between male and female COVID-19 patients. thus producing a list of top-ranked drugs that can potentially inhibit these up-regulated genes in the activated super GO terms. In parallel, the activated core signaling network caused by viral infection within host cells was constructed by integrating viral-host protein-protein interactions, the up-regulated genes associated with the activated GO terms, as well as the bioGrid proteinprotein interaction network, and fold change values of all the genes as found in the RNA-seq data.

Then, drug-target interaction information was derived from drugBank, and drugs that target the inferred signaling network proteins were identified as potential candidates for repurposing for SARS-CoV-2 replication inhibition and resultant COVID-19 treatment. The details of the related datasets and methods are described further in the following sections. All database and datasets used in this study are open and publicly available.

The 3D cryo-electron microscopy (cryo-EM) structure of the protein complex associated with RNA-dependent RNA polymerase (RdRp), i.e., nsp12, and its two co-factors, nsp7 and nsp8, of SARS-CoV-2, has been reported upon in the literature, including in the indicated references 17, 18 .

These structures are essential contributors of viral replication, working together with the transcription machinery of host cells. The RdRp is thought to be the primary target of the antiviral drugs, like Remdesivir.

To identify the (prey) proteins binding to (bait) nsp7, nsp8 and nsp12 (and other viral proteins), protein-protein binding assays were conducted, as reported in reference 6 . Specifically, there are 20, 34, and 24 proteins interacting with nsp12, nsp7 and nsp8 respectively, and there is no overlap among these proteins. The data is available in reference 6 .

The raw counts of RNA-seq data (transcriptomic response) of A549_ACE2 (engineered with expression of ACE2 protein), and CALU-3 lung cancer cells (with ACE2 expression) cells infected by SARS-CoV-2 were available in a single dataset (GSE147507) from the Gene Expression Omnibus (GEO) database 11 . The DEseq2 19 approach was used to calculate the fold change and p-value of individual genes in the A549_ACE2, and CALU-3 lung cancer cells respectively beforeand after-exposure to SARS-CoV-2 (with 3 replications). Then up-regulated genes were obtained by using fold change >=2.0 and p-value <= 0.05. Subsequently, the overlapping (intersection)

genes between the up-regulated genes found in CALU-3 and A549_ACE2 cell lines were selected for further analysis as described below.

The Fisher's exact test was used to identify activated biological processes (BP) gene ontology (GO) 20 terms associated with the identified up-regulated genes. Then, the activated GO terms with genes in [10, 500] and p-value <= 0.05 were identified. Among the hundreds of GO terms found, we further empirically selected the potentially virus-related GO terms. To further cluster the selected GO terms into sub-groups, named super GO terms, which share the similar biological processes (GOs), the GO-GO similarity was calculated using a semantic similarity metric 21 (implemented using the GOSemSim R package), and then the affinity propagation clustering 22 (APclustering) model was employed to identify the GO sub-groups, i.e., super-GOs. The number of sub-groups was set 5 empirically.

The up-regulated genes associated with individual activated GO terms included in each super-GO terms were used as the gene set signatures to identify potentially effective drugs that can inhibit the activated biological function using the connectivity map (CMAP) 15 Based on the average GSEA scores, the top ranked drugs were selected.

Transcription factors (TFs) are important when exploring regulatory networks. To investigate which set of TFs were up-regulated after SARS-CoV-2 infection in the 2 lung tumor cells use in our study, TF information was derived from the molecular signature database (MSigDB) 24 .

Specifically, the C3 category molecular signatures were obtained, which corresponded to regulatory gene sets. From those, 415 TFs interacting with 14802 target genes were identified.

The protein-protein interaction (PPI) network for these genes was derived from BioGRID 25 and used as a background signaling network. There were approximately 21,699 genes and 368,918

interactions identified using this approach. The RdRp consequent signaling network inference was defined as a sub-network inference problem within BioGRID. Here, we proposed a novel consequent signaling network inference model. Specifically, let ! " = 〈 " , ∅〉 denote the initialized consequent signaling network of root nodes " . The root nodes are the proteins interacting with the nsp12, nsp7 and nsp8. The growth update of the consequent signaling was defined as: The FDA approved drug and their target information was derived from drugbank 14 database. The genes, with degree >= 10, in the RdRp-host signaling network were selected. Then the FDA approved drugs inhibiting the selected genes were identified as drug candidates that can potentially perturb the uncovered signaling network.

As described in the methods section, 656 overlapping (intersection) genes were identified between 1,335 and 2,260 up-regulated genes identified in the CALU-3 and A549_ACE2 cell lines respectively with the fold change >=2.0 and p-value <= 0.05. Via GO enrichment analysis, 474

GO terms in the BP category were identified with a p-value of <= 0.05, and the number of genes in these GO terms was within a range of 10 to 500. Among these identified GO terms, the wellknown inflammation and innate immune related GOs terms were identified. As we described in the methods section, given that we aimed to identify the essential host transcription factors that generate proteins which interact with the RdRp of SARS-CoV-2 and its co-factors for viral replications, these inflammation and immune response related GO terms were filtered out empirically. Subsequently, 96 GO terms were finally selected (see supplementary Table 1 ), in which the 299 activated genes (out of the 656 genes) were included (see supplementary Table   2 ). As seen, a large set of inflammation and immune response related signaling processes were activated, which indicated the strong inflammation and immune response. In addition, a set of core signaling pathways, like PI3K, ERK1/2, NFkB, JAK-STAT, p38MAPK, JNK, were activated, which are the potential therapeutic targets, like JAK2, for identifying potentially effective COVID- Further, the 96 activated GOs were clustered into 5 sub-groups, i.e., super-GO terms (see 

Using the up-regulated genes found in the 5 super-GOs, we identified drugs that can potentially inhibit these activated super-GO terms. Drugs and compounds that had a CMAP drug ranking score of <= -85 (indicating that these drug compounds could inhibit the activated gene set signatures in each super-GO term) were selected. Fig. 3 shows the top-ranked drug categories.

Interestingly, the estrogen hormones, estrone (E1) and estriol (E3, weak estrogen hormones), which interact with ESR1/2, as well as estradiol, were top-ranked to be able to inhibit the inflammation and immune response-related biomarker genes in the super-GO terms. As seen, azithromycin, chloroquine, dexamethasone, fluoxetine, formoterol, lenalidomide, losartan, progesterone, ramipril, sildenafil, simvastatin, sitagliptin, tacrolimus, thalidomide and verapamil.

Simvastatin 29 , losartan 30 , and chloroquine + azithromycin (used to treat bacterial infections) 31 have also showed potential efficacy in COVID-19 treatments. SSRI inhibitors and anti-depression drugs, like fluoxetine, were potentially effective for COVID-19 treatment 32 . Ramipril is the ACE inhibitor. The drug dexamethasone, belonging to the glucocorticoid receptor, corticosteroid agonist, and immunosuppressant categories, was the first drug reported to be able to significantly 

Two RdRp-host interaction signaling networks were generated using the proposed network analysis model described in the method section. Supplementary Fig. 1 shows the Nsp12(RdRp)host interaction signaling network linking the 299 selected genes from 20 prey proteins (root genes) that interact with nsp12 (the RdRp bait protein). There were 22,666 interactions among these 405 genes. Fig. 4 shows the Nsp12-nsp7-nsp8(RdRp)-host interaction signaling network linking the 299 selected genes from 73 prey proteins (root genes) that interact with at least one of nsp12, nsp7, nsp8 (the RdRp bait protein). There were 3,373 interactions among these 486

genes. There are 395 overlapping genes between the two signaling networks, which indicated that the nsp12-host signaling network is a subnetwork of the nsp12-nsp7-nsp8-host signaling network. As seen in the center area of the signaling networks, ESR1 and ESR2, the signaling receptors of estrogen hormones, were identified in the viral-host interaction signaling network, which indicated that ESR1 and ESR2 play important roles in viral-host interactions. In addition, 

There were 200 genes with node degree >=10 in at least one of the two RdRp-host interaction signaling networks (see supplementary . 6-upper panel) . Of note, we further downloaded the mortality data of male and female (see Fig. 6 -bottom panel) in U.S. from the CDC website 46 (by December 31, 2020), and compared those data with the estrogen levels of female over their life span 45 (see Fig. 6-upper   panel) . Surprisingly, the trends of the two curves closely approximated each-other (i.e., the curve of ratio between female and male mortality rate of COVID-19 patients vs the cure of levels of female). This specific findings might be able to explain, in terms of the molecular mechanism, the mounting evidence suggesting that men have a significantly higher mortality rate when positive for COVID-19 than young women 47 . In other words, the low level of estoren hormone in female before 9 years old, and the dramatic decreasing of estradiol after ~55 years of age is associated 

Millions of people are being infected by SARS-CoV-2 globally, with thousands of ensuing deaths every day. There is currently a lack of effective treatments to reduce the mortality rate of COVID-19. Further, given the slow rates of vaccine delivery throughout the glove, and the emergence of new SARS-CoV-2 variants, the need for new and effective treatments is both critical and unlikely to cease to be a priority for the foreseeable future. Remdesivir is a widely used and promising drug inhibiting the RdRp protein. However, the evidence of efficacy of using Remdesivir alone is limited. To improve the efficacy of Remdesivir, one possible approach is to combine Remdesivir with other drugs that can inhibit the down-stream signaling of RdRp.

Sex had been indicated as an essential factor in the mortality of COVID-19. The global data of COVID-19 showed that men have a higher mortality rate than women. Therefore, the sex difference indicated that sex related genetic factors could be an interesting mechanism and targets for COVID-19 treatment, combined with existing treatment options. However, the underlying targets and signaling pathways associated with the sex difference remain unclear.

Using the systematic and integrative network analysis models, we identified estrogen hormones (ER), interacting with ESR1 and ESR2, are essential sex factors causing distinct mortality patterns in female and male COVID-19 patients. Specifically, a high level of estradiol protects young female COVID-19 patients, and estrogen loss to an extremely low level in females after about 55 years of age causes the increased fatality rate of women. Moreover, estrogen hormones can be effective treatments for COVID-19 by inhibiting the inflammation and immune response within host cells caused by SARS-CoV-2. These novel molecular mechanisms could provide clues to develop novel and effective treatments for COVID-19. One challenge is that it remains unclear and difficult to identify the 'causal' down-stream signaling interactions of the sex associated genetic factors among the host signaling network to regulate inflammation and immune response.

For example, it is interesting and important to further study the molecular mechanism of how the ESR1 and ESR2, or the other essential sex associated genetic factors interact with other signaling targets to regulate host cell response (like inflammation and immune response).

In this study, we conclude that estrogen hormone is an essential sex factor causing the distinct fatality rates between male and female COVID-19 patients. Specifically, a high level of estradiol protecting young female COVID-19 patients, and estrogen loss to an extremely low level in females after about 55 years of age causing the increased fatality rate of women. In addition, the uncovered essential host targets and treatments can help designing experimental validations to uncover effective targets and drugs along or combined with Remdesivir as novel treatment regimens of COVID-19.

An interactive web-based dashboard to track COVID-19 in real time

Estimates of the severity of coronavirus disease 2019: a model-based analysis

Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary

Sex differences in COVID-19 case fatality: do we know enough? The Lancet Global Health

Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission

A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing

Rapid repurposing of drugs for COVID-19

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

The Global Phosphorylation Landscape of SARS-CoV-2 Infection

Systems-level immunomonitoring from acute to recovery phase of severe COVID-19

SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems

Proteomics of SARS-CoV-2-infected host cells reveals therapy targets

Genome-wide CRISPR screen reveals host genes that regulate SARS-CoV-2 infection

DrugBank 5.0: A major update to the DrugBank database for

The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease

A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Gene Ontology: tool for the unification of biology NIH Public Access Author Manuscript

GOSemSim: An R package for measuring semantic similarity among GO terms and gene products

Clustering by passing messages between data points

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Molecular signatures database (MSigDB) 3.0

The BioGRID interaction database: 2019 update

GABA administration prevents severe illness and death following coronavirus infection in mice

FDA approved calcium channel blockers inhibit SARS-CoV-2 infectivity in epithelial lung cells

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Meta-analysis of Effect of Statins in Patients with COVID-19

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients with Symptomatic COVID-19: A Randomized Clinical Trial

Potential Treatments for COVID-19; a Narrative Literature Review. Archives of academic emergency medicine

COVID-19: Melatonin as a potential adjuvant treatment

ACE2 expression is increased in the lungs of patients with comorbidities associated with severe COVID-19

Management of epigenomic networks entailed in coronavirus infections and COVID-19

TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib

Repurposing of Kinase Inhibitors for Treatment of COVID-19

Is targeting akt a viable option to treat advanced-stage COVID-19 patients?

Targeting MDM2-dependent serine metabolism as a therapeutic strategy for liposarcoma

Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment

The role of growth factor receptors in viral infections: An opportunity for drug repurposing against emerging viral diseases such as COVID-19?

Drugs and Clinical Approaches Targeting the Antiapoptotic Protein: A Review

COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome

Sex-specific genetic architecture of human disease

Gender Differences in Patients With COVID-19: Focus on Severity and Mortality

We would like to thank Dr. Jennifer Philips for the helpful discussions and revision.

This is a list of supplementary les associated with this preprint. Click to download.

SexFactorCovid19srsuppTables.docx